Abstract: A method of providing symptomatic relief from sleep induced insomnia in a patient comprising administering an effective amount of R-(+)-?-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.

Abstract: Methods for preventing ulcers, such as gastric ulcers, in a horse about to undergo stress that causes gastric ulcers and prior to occurrence of a gastric ulcer condition in the horse involving administering a proton pump inhibitor (PPI) are disclosed and claimed.

Abstract: A liquid pharmaceutical composition is described comprising from about 7.5 mg/mL to about 12.5 mg/mL of midazolam in the form of midazolam maleate in solution in an aqueous liquid medium comprising ethanol and a polyhydroxy solvent. This composition can be administered by the buccal route for the treatment of patients suffering epileptic siezures or as an anaesthetic.

Abstract: The present invention relates to a composition comprising alpha-hydroxy propionic acid linked to any pharmaceutically acceptable vehicle, such as pure serum, 1,2,3-propanetriol, 1,2-propanediol resp. a mixture thereof or optionally a pharmaceutically acceptable catalyzer. Alpha-hydroxy-propionic acid is used in medicine in many dilutions for the treatment of sinusitis and other upper respiratory diseases. The present invention is characterized by a formulation adapted to nasal delivery for the treatment of upper respiratory disorders.

Abstract: The invention relates to the use of mirtazapine for the preparation of a medicine for a new method of treatment of a sleep disorder in a subject, which treatment comprises the administration of mirtazapine with a unit treatment dose comprising between 0.1 and 5 mg mirtazapine and relates to a patient pack for the treatment of sleep disorders.

Abstract: A method of treating tumors with radiation is disclosed, wherein the tumor is sensitized by administering a tumor sensitizing agent comprising 5-chloro-2?-deoxycytidine, 4-N-methyl FdC and a cytidine deaminase inhibitor to a patient having the tumor. The tumor is then subjected to radiation.

Abstract: The present invention is directed to an analgesic composition which consists essentially of a cyclooxygenase-2 inhibitor and a compound selected from the group consisting of non-steroidal anti-inflammatory drugs, acetaminophen and mixtures thereof. The present invention further is directed to a method for inducing analgesia through the administration of such a composition to a patient.

Abstract: This invention relates to compositions comprising thalidomide and irinotecan, which can be used in the treatment or prevention of colorectal cancer. The invention also relates to methods of treating or preventing colorectal cancer which comprise the administration of thalidomide and irinotecan to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of irinotecan which comprise the administration of thalidomide to a patient in need of such reduction or avoidance.

Abstract: The present invention concerns the use of nicotine or a derivative thereof for producing a drug for continuous or progressive administration of 0.2 mg to 5 mg per day per kilogram of body weight in man, said drug being administered simultaneously with L-DOPA in a dose at least 30% lower than the effective dose when L-DOPA is administered alone.

Abstract: Methods of treating and inhibiting cancer in animals by administering a therapeutically effective amount of a pharmaceutical composition having benzimidazole of the general formula: wherein X is hydrogen, halogen, alkyl of less than 7 carbon atoms or alkoxy of less than 7 carbon atoms; n is a positive integer of less than 4; Y is hydrogen, chlorine, oxychloro, nitro, methyl or ethyl; and R is hydrogen, or an alkyl group of from 1 to 8 carbon atoms and R2 is NHCOOR1 wherein R1 is aliphatic hydrocarbon of less than 7 carbon atoms, and preferably an alkyl group of less than 7 carbon atoms and pharmaceutically acceptable derivatives alone, or in combination, or in conduction with other therapeutic agents such as other cancer inhibiting compounds, and operative combinations thereof.

Abstract: 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the treatment of sub-type anxiety disorders chosen from the sub-types: panic disorder with or without agoraphobia, agoraphobia, obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized anxiety disorder, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, anorexia, and fibromyalgia. A preferred salts is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.

Abstract: The present invention is directed to a liquid formulation of metformin or its pharmaceutically acceptable salts thereof. The liquid pharmaceutical composition comprises a therapeutically effective amount of metformin or its pharmaceutically acceptable salt, in a liquid carrier, which may also include a sweetener that does not increase the blood glucose level of a subject after ingestion thereof. In one embodiment, it may also include alkyl hydroxyethylcellulose, and/or a polyhydroxy alcohol. In another embodiment, the carrier may contain a sweetener, mineral acid, and bicarbonate salt maintained at a pH of 4.0 to 9.0. It is useful for treating hyperglycemia and diabetes.

Abstract: A series of compounds of natural origin are described, as useful agents for the treatment of diseases characterised by abnormal angiogenesis. These compounds are: chrysanthone A having formula (I); chrysanthone B having formula (II); and chrysanthone C having formula (III).

Abstract: The present invention concerns the use of cloricromene (8-chloro-3(?-diethylaminoethyl)-4-methyl-7-ethoxycarbonylmethoxy coumarin) base and the salts thereof to prepare pharmaceutical compositions with cholesterol-lowering activity.

Abstract: The present invention relates to a pharmaceutical preparation containing at least one compound of general formula (I) wherein R1 and R2 are each independently of each other a straight-chain or branched alkyl residue having 1 to 30 carbon atoms, a straight-chain or branched alkenyl residue having 2 to 30 carbon atoms, a monocyclic or polycyclic alkyl residue having 3 to 30 carbon atoms, a monocyclic or polycyclic alkenyl residue having 4 to 30 carbon atoms, or a monocyclic or polycyclic aromatic residue having 6 to 30 carbon atoms, these residues being optionally substituted by one or several substituents. This invention also relates to the use of the pharmaceutical preparations for the immunosuppressive treatment and for the non-invasive treatment.

Abstract: (R)-N-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl]nipecotic acid and salts thereof are effective GABA uptake inhibitory compounds and exert pharmacological effects on pain associated with diabetic neuropathy and migraine.

Abstract: A method for inhibiting bone metastasis of a malignant tumor in a patient who has a cancer excluding breast cancer comprises administering to said patient an effective amount of a compound of the formula (III): wherein R2 represents a C1-C10 alkyl group substituted by one or more hydroxyl groups is provided.

Abstract: The present invention provides a diuretic, sodium ion-excreting agent, medicament for preventing or treating hypertension, medicament for preventing or treating ischemic cardiac diseases, medicament for preventing or treating congestive cardiac insufficiency or medicament for preventing or treating renal diseases, which comprises ?-tocotrienol.

Abstract: Disorders mediated by p38 kinase inhibitors are treated with compounds of the formula: or salts thereof, wherein: R1 is hydrogen or alkyl; R2 is substituted cycloalkyl, heterosubstituted cycloalkyl, helcroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl-alkly, heterocyclyl, heterocyclyl spiro cycloalkyl, aralkoxy, alkoxy, -alkylene-S(O)n-alkyl (where is 1 or 2) or —SO2Ar2; R3 is hydrogen, amino, monoalkylamino, dialkylamino, acylamino, —NR8—C(?O)—Rb (where Ra is hydrogen or alkyl and Rh is heterocyclyl or heteroalkyl), alkyl, cycloalkyl, phthalimidoalkyl, aryl, aralkyl, haloalkyl, heteroalkyl, cyanoalkyl, -alkylene-C(O) R (where R is hydrogen, alkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino) or acyl; and each of Ar1 and Ar2 is independently aryl.

Abstract: A method of inhibiting cell proliferation in a patient suffering from such disorder comprising administering to said patient an effective amount of a composition comprising, in admixture with a pharmaceutically acceptable carrier, a compound, or a pharmaceutically acceptable salt thereof, which is a substituted styrene compound which can also be a naphthalene, an indane or a benzoxazine; including nitrile and molononitrile compounds, and pharmaceutical compositions comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of such compound.